리소좀병 치료 시장 보고서(2026년)

Lysosomal diseases (LSDs) are conditions in which excessive substrates accumulate within the cells of various organs due to impaired lysosomal function. This buildup of materials inside lysosomes causes damage to multiple tissues and organs, leading to a broad range of symptoms that can affect different parts of the body.

The main types of lysosomal disease treatments address conditions such as mucopolysaccharidosis, Pompe syndrome, Fabry disease, Gaucher's disease, and others. Mucopolysaccharidosis type I (MPS I) is a lysosomal disorder caused by a deficiency of the enzyme alpha-L-iduronidase (IDUA) and is treated using enzyme replacement therapy (ERT) and/or hematopoietic stem cell transplantation (HSCT). These diseases are managed through therapies including substrate reduction therapy, stem cell therapy, enzyme replacement therapy, and other treatment approaches, administered via oral, parenteral, and other routes. Treatment is provided across hospitals, specialty clinics, home care settings, and other end-user environments.

Tariffs have affected the lysosomal disease treatment market by increasing the cost of imported biopharmaceuticals, laboratory equipment, and raw materials used in drug production. The segments most impacted include enzyme replacement therapy and substrate reduction therapy, particularly in regions such as North America and Europe that rely on imported therapeutics. While tariffs have created challenges by raising costs and slowing supply chains, they have also incentivized local manufacturing and innovation in domestic production of treatments, creating potential long-term benefits for market resilience.

The lysosomal disease treatment market research report is one of a series of new reports from The Business Research Company that provides lysosomal disease treatment market statistics, including lysosomal disease treatment industry global market size, regional shares, competitors with a lysosomal disease treatment market share, detailed lysosomal disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the lysosomal disease treatment industry. This lysosomal disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lysosomal disease treatment market size has grown strongly in recent years. It will grow from $9.79 billion in 2025 to $10.56 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to advancements in enzyme replacement therapies, increasing awareness of lysosomal storage disorders, growth of pediatric care infrastructure, government funding for rare disease research, emergence of diagnostic technologies.

The lysosomal disease treatment market size is expected to see strong growth in the next few years. It will grow to $14.73 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to expansion of personalized medicine, rising adoption of gene therapy, increased investments in biotechnology, growth in emerging markets healthcare infrastructure, partnerships for rare disease drug development. Major trends in the forecast period include development of targeted enzyme replacement therapies, expansion of rare disease diagnostic capabilities, growth of pediatric and adult treatment programs, increase in personalized and precision medicine approaches, rising collaborations between pharma and research institutes.

The expansion of diagnostic activities is anticipated to drive the growth of the lysosomal disease treatment market. Diagnostic activities involve systematic tests and procedures used to detect and evaluate diseases, supporting accurate clinical decision-making and treatment planning. The growth of these activities is supported by advances in medical technology, the rising prevalence of chronic conditions, increased emphasis on preventive healthcare, greater awareness of rare diseases, and favorable government policies and healthcare funding. As diagnostic capabilities become more advanced, healthcare providers are able to identify lysosomal disorders with greater precision, which in turn stimulates investment in targeted therapies and treatment options. For example, in May 2023, according to the National Health Service, 2,302,400 diagnostic tests were carried out in March 2023, representing an increase of 223,100 tests compared with March 2022. By the end of March 2023, the number of patients awaiting a key diagnostic test reached 1,628,300, an increase of 59,400 year over year. Therefore, the rise in diagnostic activities is contributing to the growth of the lysosomal disease treatment market.

Companies operating in the lysosomal disease treatment market are increasingly emphasizing advancements in research and technology to strengthen their competitive position. Progress in scientific research and technological innovation enables the development of more effective and targeted therapies for rare lysosomal disorders. For instance, in September 2023, Amicus Therapeutics announced that the U.S. Food and Drug Administration approved Pombiliti (cipaglucosidase alfa-atga) in combination with Opfolda (miglustat) 65 mg capsules for the treatment of adults with late-onset Pompe disease. This two-component therapy combines cipaglucosidase alfa-atga, a bis-M6P-enriched recombinant human acid alpha-glucosidase designed for enhanced cellular uptake via the M6P receptor, with the oral enzyme stabilizer miglustat, which helps reduce enzyme activity loss in the bloodstream.

In March 2024, CENTOGENE, a Germany-based specialist in rare disease diagnostics and multiomic data insights, partnered with Takeda to accelerate the development of treatments for rare genetic diseases. Through this partnership expansion, CENTOGENE aims to deepen its collaboration with Takeda by leveraging its proprietary multiomic technology platform to speed up the discovery and development of innovative therapies for rare genetic conditions.

Major companies operating in the lysosomal disease treatment market are Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Sanofi SA, Pfizer Inc., Novartis International AG, Johnson & Johnson Services Inc., Alexion Pharmaceuticals Inc., Amicus Therapeutics Inc., Actelion Pharmaceuticals Ltd., Sigilon Therapeutics Inc., BioMarin Pharmaceutical Inc., Merck & Co Inc., AstraZeneca PLC, Astellas Pharma Inc., Horizon Therapeutics plc, Leadient Biosciences Inc., Orphazyme A/S, Recordati Industria Chimica e Farmaceutica S.p.A., Valerion Therapeutics Llc, Viatris Inc., Chiese Farmaceutici SpA, Genzyme Corporation, Ultragenyx Pharmaceutical Inc., Sangamo Therapeutics Inc., Avrobio Inc., Axovant Gene Therapies Ltd., Regenxbio Inc., Krystal Biotech Inc., Homology Medicines Inc., Orchard Therapeutics plc, Sarepta Therapeutics Inc., Solid Biosciences Inc.

North America was the largest region in the lysosomal disease treatment market in 2025. Europe is expected to be the fastest-growing region in the global lysosomal disease treatment market report during the forecast period. The regions covered in the lysosomal disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lysosomal disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lysosomal disease treatment market includes revenues earned by entities by offering lysosomal disease treatment services for inherited lysosomal disorders such as neuronal ceroid lipofuscinoses, Danon disease, and Wolman disease, and diagnosis of the disease through medication and therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The lysosomal disease treatment market consists of sales of medicines and services such as Bone marrow transplantation, the use of molecular chaperones, and Gene therapy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lysosomal Disease Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses lysosomal disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lysosomal disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lysosomal disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Disease Type: Mucopolysaccharidosis; Pompe Syndrome; Fabry Diseases; Gaucher's Disease; Other Disease Types
• 2) By Therapy: Substrate Reduction Therapy; Stem Cell Therapy; Enzyme Replacement Therapy; Other Therapies
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By End User: Hospitals; Specialty Clinics; Homecare; Other End Users
• Subsegments:
• 1) By Mucopolysaccharidosis: MPS I (Hurler Syndrome); MPS II (Hunter Syndrome); MPS III (Sanfilippo Syndrome); MPS IV (Morquio Syndrome); MPS VI (Maroteaux-Lamy Syndrome); MPS VII (Sly Syndrome)
• 2) By Pompe Syndrome: Late-Onset Pompe Disease; Infantile-Onset Pompe Disease
• 3) By Fabry Disease: Classic Fabry Disease; Late-Onset Fabry Disease
• 4) By Gaucher's Disease: Type 1 Gaucher Disease; Type 2 Gaucher Disease; Type 3 Gaucher Disease
• 5) By Other Disease Types: Niemann-Pick Disease; Krabbe Disease; Tay-Sachs Disease
• Companies Mentioned: Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Sanofi SA; Pfizer Inc.; Novartis International AG; Johnson & Johnson Services Inc.; Alexion Pharmaceuticals Inc.; Amicus Therapeutics Inc.; Actelion Pharmaceuticals Ltd.; Sigilon Therapeutics Inc.; BioMarin Pharmaceutical Inc.; Merck & Co Inc.; AstraZeneca PLC; Astellas Pharma Inc.; Horizon Therapeutics plc; Leadient Biosciences Inc.; Orphazyme A/S; Recordati Industria Chimica e Farmaceutica S.p.A.; Valerion Therapeutics Llc; Viatris Inc.; Chiese Farmaceutici SpA; Genzyme Corporation; Ultragenyx Pharmaceutical Inc.; Sangamo Therapeutics Inc.; Avrobio Inc.; Axovant Gene Therapies Ltd.; Regenxbio Inc.; Krystal Biotech Inc.; Homology Medicines Inc.; Orchard Therapeutics plc; Sarepta Therapeutics Inc.; Solid Biosciences Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Lysosomal Disease Treatment Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Lysosomal Disease Treatment Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Lysosomal Disease Treatment Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Lysosomal Disease Treatment Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Artificial Intelligence & Autonomous Intelligence
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Development Of Targeted Enzyme Replacement Therapies
  • 4.2.2 Expansion Of Rare Disease Diagnostic Capabilities
  • 4.2.3 Growth Of Pediatric And Adult Treatment Programs
  • 4.2.4 Increase In Personalized And Precision Medicine Approaches
  • 4.2.5 Rising Collaborations Between Pharma And Research Institutes

5. Lysosomal Disease Treatment Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Homecare Providers
• 5.4 Research & Diagnostic Centers
• 5.5 Pharmacies

6. Lysosomal Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Lysosomal Disease Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Lysosomal Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Lysosomal Disease Treatment Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Lysosomal Disease Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Lysosomal Disease Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Lysosomal Disease Treatment Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Lysosomal Disease Treatment Market Segmentation

• 9.1. Global Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Mucopolysaccharidosis, Pompe Syndrome, Fabry Diseases, Gaucher's Disease, Other Disease Types
• 9.2. Global Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy, Other Therapies
• 9.3. Global Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Parenteral, Other Routes Of Administration
• 9.4. Global Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Specialty Clinics, Homecare, Other End Users
• 9.5. Global Lysosomal Disease Treatment Market, Sub-Segmentation Of Mucopolysaccharidosis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• MPS I (Hurler Syndrome), MPS II (Hunter Syndrome), MPS III (Sanfilippo Syndrome), MPS IV (Morquio Syndrome), MPS VI (Maroteaux-Lamy Syndrome), MPS VII (Sly Syndrome)
• 9.6. Global Lysosomal Disease Treatment Market, Sub-Segmentation Of Pompe Syndrome, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Late-Onset Pompe Disease, Infantile-Onset Pompe Disease
• 9.7. Global Lysosomal Disease Treatment Market, Sub-Segmentation Of Fabry Disease, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Classic Fabry Disease, Late-Onset Fabry Disease
• 9.8. Global Lysosomal Disease Treatment Market, Sub-Segmentation Of Gaucher's Disease, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Type 1 Gaucher Disease, Type 2 Gaucher Disease, Type 3 Gaucher Disease
• 9.9. Global Lysosomal Disease Treatment Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Niemann-Pick Disease, Krabbe Disease, Tay-Sachs Disease

10. Lysosomal Disease Treatment Market Regional And Country Analysis

• 10.1. Global Lysosomal Disease Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Lysosomal Disease Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Lysosomal Disease Treatment Market

• 11.1. Asia-Pacific Lysosomal Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Lysosomal Disease Treatment Market

• 12.1. China Lysosomal Disease Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Lysosomal Disease Treatment Market

• 13.1. India Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Lysosomal Disease Treatment Market

• 14.1. Japan Lysosomal Disease Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Lysosomal Disease Treatment Market

• 15.1. Australia Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Lysosomal Disease Treatment Market

• 16.1. Indonesia Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Lysosomal Disease Treatment Market

• 17.1. South Korea Lysosomal Disease Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Lysosomal Disease Treatment Market

• 18.1. Taiwan Lysosomal Disease Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Lysosomal Disease Treatment Market

• 19.1. South East Asia Lysosomal Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Lysosomal Disease Treatment Market

• 20.1. Western Europe Lysosomal Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Lysosomal Disease Treatment Market

• 21.1. UK Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Lysosomal Disease Treatment Market

• 22.1. Germany Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Lysosomal Disease Treatment Market

• 23.1. France Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Lysosomal Disease Treatment Market

• 24.1. Italy Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Lysosomal Disease Treatment Market

• 25.1. Spain Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Lysosomal Disease Treatment Market

• 26.1. Eastern Europe Lysosomal Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Lysosomal Disease Treatment Market

• 27.1. Russia Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Lysosomal Disease Treatment Market

• 28.1. North America Lysosomal Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Lysosomal Disease Treatment Market

• 29.1. USA Lysosomal Disease Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Lysosomal Disease Treatment Market

• 30.1. Canada Lysosomal Disease Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Lysosomal Disease Treatment Market

• 31.1. South America Lysosomal Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Lysosomal Disease Treatment Market

• 32.1. Brazil Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Lysosomal Disease Treatment Market

• 33.1. Middle East Lysosomal Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Lysosomal Disease Treatment Market

• 34.1. Africa Lysosomal Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Lysosomal Disease Treatment Market, Segmentation By Disease Type, Segmentation By Therapy, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Lysosomal Disease Treatment Market Regulatory and Investment Landscape

36. Lysosomal Disease Treatment Market Competitive Landscape And Company Profiles

• 36.1. Lysosomal Disease Treatment Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Lysosomal Disease Treatment Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Lysosomal Disease Treatment Market Company Profiles
  • 36.3.1. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

37. Lysosomal Disease Treatment Market Other Major And Innovative Companies

• Johnson & Johnson Services Inc., Alexion Pharmaceuticals Inc., Amicus Therapeutics Inc., Actelion Pharmaceuticals Ltd., Sigilon Therapeutics Inc., BioMarin Pharmaceutical Inc., Merck & Co Inc., AstraZeneca PLC, Astellas Pharma Inc., Horizon Therapeutics plc, Leadient Biosciences Inc., Orphazyme A/S, Recordati Industria Chimica e Farmaceutica S.p.A., Valerion Therapeutics Llc, Viatris Inc.

38. Global Lysosomal Disease Treatment Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Lysosomal Disease Treatment Market

40. Lysosomal Disease Treatment Market High Potential Countries, Segments and Strategies

• 40.1 Lysosomal Disease Treatment Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Lysosomal Disease Treatment Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Lysosomal Disease Treatment Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer